Efficacy of Bevacizumab and a Bevacizumab-Methylcellulose Mixture on Intraocular Pressure After Deep Sclerectomy: A Double-Blind, Randomized Controlled Clinical Trial
Journal of Research in Clinical Medicine · 13.05.2026 · 14 · 34906
DOI: 10.34172/jrcm.026.34906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Research in Clinical Medicine, online erschienen am 13.05.2026. Verfasst von Ali Mostafaei und 3 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study aimed to compare the effectiveness of bevacizumab administered alone versus combined with methylcellulose in reducing intraocular pressure during a six-month period following deep sclerectomy.
Methods
This comparative investigation, serving as an extension of a prospective randomized controlled trial, enrolled 30 eyes from 30 individuals diagnosed with open-angle glaucoma (15 eyes assigned to each treatment arm). Among participants, 33.3% presented with secondary open-angle glaucoma (pseudoexfoliation syndrome), while 66.7% had primary open-angle glaucoma requiring deep sclerectomy. Postoperatively, Group A received subconjunctival bevacizumab injections, whereas Group B received subconjunctival injections of a bevacizumab-methylcellulose mixture. Primary outcome measures included surgical success rates and bleb morphology assessment.
Results
Among eligible participants, 66.7% were male and 33.3% were female. Visual acuity measurements demonstrated no significant intergroup differences before or after surgery. Although Group B exhibited greater IOP reduction compared to Group A, statistically significant differences between groups emerged only at postoperative day one and at the six-month follow-up assessment. Success rates (complete or relative success) at six months showed no statistically significant variation between groups (*P*>0.05), nor did mean preoperative and postoperative values with standard deviations differ significantly. Vascularity scores decreased markedly in Group B at one-month, three-month, and six-month evaluations relative to Group A.
Conclusion
Utilizing a sustained-release delivery system that extends bevacizumab bioavailability appears to enhance surgical outcomes compared to conventional isolated bevacizumab ocular injections. Trial Registration: IRCT2016121831450N1
Zitieren
APA
Mostafaei, A., Taheri, N., Moghaddam, N., & Salehi-Pourmehr, H. (2026). Efficacy of Bevacizumab and a Bevacizumab-Methylcellulose Mixture on Intraocular Pressure After Deep Sclerectomy: A Double-Blind, Randomized Controlled Clinical Trial. Journal of Research in Clinical Medicine, 14, 34906. https://doi.org/10.34172/jrcm.026.34906
Vancouver
Mostafaei A, Taheri N, Moghaddam N, Salehi-Pourmehr H. Efficacy of Bevacizumab and a Bevacizumab-Methylcellulose Mixture on Intraocular Pressure After Deep Sclerectomy: A Double-Blind, Randomized Controlled Clinical Trial. Journal of Research in Clinical Medicine. 2026;14:34906. doi:10.34172/jrcm.026.34906
BibTeX
@article{Mostafaei2026,
author = {Mostafaei, Ali and Taheri, Nazli and Moghaddam, Neda and Salehi-Pourmehr, Hanieh},
title = {Efficacy of Bevacizumab and a Bevacizumab-Methylcellulose Mixture on Intraocular Pressure After Deep Sclerectomy: A Double-Blind, Randomized Controlled Clinical Trial},
journal = {Journal of Research in Clinical Medicine},
year = {2026},
volume = {14},
pages = {34906},
doi = {10.34172/jrcm.026.34906}
}
EUVIMED